Comparison · NCT00777179-5b4022f6
Vandetanib vs Placebo: Objective Response Rate (ORR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib vs Placebo: Objective Response Rate (ORR). Trial comparisons, record NCT00777179-5b4022f6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00777179-5b4022f6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.187 | 0.115 | 0.289 | wilson | |
| Risk in group 2 | 0.0238 | 0.00422 | 0.123 | wilson | |
| Risk difference, group 1 minus group 2 | 0.163 | 0.0401 | 0.267 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 7.84 | 1.07 | 57.5 | log | |
| Odds ratio, group 1 over group 2 | 9.41 | 1.19 | 74.3 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib than on Placebo | 6.14 | 3.74 | 25 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib | Vandetanib 300 mg, orally, once daily | 14 | 75 | OG000 |
| Group 2 | Placebo | Matching Placebo | 1 | 42 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Response Rate (ORR)
- Description
Number of patients showing Complete Response (CR) or Partial Response (PR) based on RECIST for the best response.~Number of patients showing Complete Response (CR, disappearance of all target lesions) or Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response.
- Time frame
- Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy
- NCT number
- NCT00777179
- Phases
- PHASE2
- Conditions
- NSCLC
- Interventions
- Vandetanib, Placebo
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2011-07-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00777179?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00777179-5b4022f6